GLIMEFON-M1 Tablet
Dual Action Antidiabetic for Effective Glycemic Control
Composition
Glimepiride 1 mg + Metformin Hydrochloride 500 mg SR
- Prescription medicine
- Available to order
Overview
GLIMEFON M1 combines Glimepiride, a sulfonylurea that promotes insulin secretion, with Metformin, a biguanide that improves insulin sensitivity and reduces hepatic glucose production. This synergistic combination ensures comprehensive management of type 2 diabetes mellitus, especially in patients inadequately controlled by monotherapy.
Key Benefits
- Dual mechanism: enhances insulin release & reduces insulin resistance
- Provides better HbA1c control and postprandial glucose reduction
- Helps delay diabetes progression and prevent complications
- Improves pancreatic β-cell function
- Well-tolerated with a low risk of hypoglycemia (when used appropriately)
Indications
- Type 2 Diabetes Mellitus (when diet, exercise, and monotherapy are not enough)
- Suitable for newly diagnosed patients or those needing combination therapy
- Reduces the risk of diabetes-related cardiovascular and renal complications
